olmesartan has been researched along with pulmicort in 2 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (pulmicort) | Trials (pulmicort) | Recent Studies (post-2010) (pulmicort) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 4,995 | 1,638 | 1,785 |
| Protein | Taxonomy | olmesartan (IC50) | pulmicort (IC50) |
|---|---|---|---|
| Glucocorticoid receptor | Homo sapiens (human) | 0.0026 | |
| Progesterone receptor | Homo sapiens (human) | 0.028 | |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | 0.0029 | |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.0045 | |
| Mineralocorticoid receptor | Homo sapiens (human) | 0.014 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 1.989 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 1.1725 | |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | 0.0045 | |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.0045 | |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.0045 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
2 other study(ies) available for olmesartan and pulmicort
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |